ECSP045368A - "antagonistas de los receptores de trombina" - Google Patents

"antagonistas de los receptores de trombina"

Info

Publication number
ECSP045368A
ECSP045368A EC2004005368A ECSP045368A ECSP045368A EC SP045368 A ECSP045368 A EC SP045368A EC 2004005368 A EC2004005368 A EC 2004005368A EC SP045368 A ECSP045368 A EC SP045368A EC SP045368 A ECSP045368 A EC SP045368A
Authority
EC
Ecuador
Prior art keywords
optionally substituted
cycloalkyl
bond
ring
thrombine
Prior art date
Application number
EC2004005368A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045368(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ECSP045368A publication Critical patent/ECSP045368A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen tricíclicos sustituidos con heterocíclicos de la fórmulas su sal farmacéuticamente aceptable, en donde la línea punteada representa un enlace simple opcional; _____ - - - - - representa un enlace doble opcional; n es 0-2; Q es cicloalquilo, opcionalmente sustituido por R13 y R14; R13 y R14 se seleccionan independientemente entre alqluilo(C1-C6),cicloalquilo(C3-C8), -OH, alcoxi(C1-C6), R27 -arilalquilo(C1-C6), heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, halógeno y haloalquilo; ó R13 y R14 forman en conjunto un anillo espirocíclico ó un anillo heterospirocíclico de 3-6 átomos; Het es un grupo heteroarilo opcionalmente sustituido mono- ó bicíclico; y B es un enlace, alquileno, ó alquenileno ó alquinileno opcionalmente sustituido, en donde los sustituyentes remanentes son como se definieron en la memoria descriptiva, como así también composiciones farmacéuticas que los contienen y un método para el tratamiento de enfermedades asociadas con trombosis, aterosclerosis, restenosis, hipertensión, angina pectoris, arritmia, insuficiencia cardiaca y cáncer administrando dichos compuestos. La terapia de combinación con otros agente cardiovasculares es también reivindicada.
EC2004005368A 2002-04-16 2004-10-15 "antagonistas de los receptores de trombina" ECSP045368A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16

Publications (1)

Publication Number Publication Date
ECSP045368A true ECSP045368A (es) 2005-01-03

Family

ID=29250954

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005368A ECSP045368A (es) 2002-04-16 2004-10-15 "antagonistas de los receptores de trombina"

Country Status (33)

Country Link
US (3) US7304078B2 (es)
EP (5) EP2062890B1 (es)
JP (2) JP4558331B2 (es)
KR (1) KR101026929B1 (es)
CN (1) CN1659162B (es)
AR (1) AR039570A1 (es)
AT (3) ATE455774T1 (es)
AU (1) AU2003221932B2 (es)
BR (1) BRPI0309309B8 (es)
CA (1) CA2482858C (es)
CY (3) CY1107184T1 (es)
DE (3) DE60317493T3 (es)
DK (2) DK1495018T3 (es)
EC (1) ECSP045368A (es)
ES (3) ES2357876T3 (es)
FR (1) FR15C0047I2 (es)
IL (1) IL164585A (es)
LT (1) LTC1495018I2 (es)
LU (1) LU92759I2 (es)
MX (1) MXPA04010308A (es)
MY (1) MY144040A (es)
NL (1) NL300746I2 (es)
NO (2) NO330500B1 (es)
NZ (2) NZ575139A (es)
PE (1) PE20040412A1 (es)
PL (1) PL214718B1 (es)
PT (2) PT2065384E (es)
RU (2) RU2329264C9 (es)
SG (1) SG164279A1 (es)
SI (2) SI1495018T1 (es)
TW (1) TWI343919B (es)
WO (1) WO2003089428A1 (es)
ZA (1) ZA200408342B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
CA2567981C (en) * 2004-05-28 2010-08-31 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
EP1799243B1 (en) * 2004-10-06 2015-07-15 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
EP2399912B1 (en) * 2005-01-14 2015-02-25 Merck Sharp & Dohme Corp. An exo-selective synthesis of himbacine analogs
CN102757423B (zh) 2005-01-14 2016-04-20 先灵公司 喜巴辛类似物的外型和非对映立体选择合成
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
MX2007008631A (es) * 2005-01-14 2007-09-12 Schering Corp Sintesis de analogos de himbacina.
US20060172397A1 (en) * 2005-01-14 2006-08-03 Schering Corporation Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
WO2006105217A2 (en) * 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
WO2007075808A2 (en) * 2005-12-20 2007-07-05 Schering Corporation Methods for preventing and/or treating a cell proliferative disorder
CN101384259A (zh) * 2005-12-22 2009-03-11 先灵公司 作为预防来自心肺外科手术的并发症的凝血酶受体拮抗剂
AR060354A1 (es) * 2006-04-06 2008-06-11 Schering Corp Terapias de combinacion antagonistas receptor trombina (tra)
EP2266976B1 (en) * 2006-04-13 2013-07-31 Merck Sharp & Dohme Corp. Fused ring thrombin receptor antagonists
AR061664A1 (es) * 2006-06-29 2008-09-10 Schering Corp Derivados de himbacina como antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. composiciones farmaceuticas.
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
CN101553484A (zh) * 2006-10-04 2009-10-07 先灵公司 以喜巴辛的被改质三环单位为基础的凝血酶受体拮抗剂
EP2069326B1 (en) * 2006-10-04 2015-03-18 Merck Sharp & Dohme Corp. Bicyclic and tricyclic derivatives as thrombin receptor antagonists
MX2009006873A (es) * 2006-12-22 2009-07-03 Schering Corp Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.
MX2009010268A (es) * 2007-03-23 2009-11-09 Schering Corp Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina.
NZ587142A (en) 2008-02-05 2012-04-27 Sanofi Aventis Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
MY152040A (en) 2008-02-05 2014-08-15 Sanofi Aventis Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
US8148363B2 (en) 2008-05-19 2012-04-03 Schering Corporation Heterocyclic compounds as factor IXA inhibitors
SI2438060T1 (sl) * 2009-06-04 2014-04-30 Merck Sharp & Dohme Corp. Aktivni metabolit trombin receptorskega antagonista
MX2011013091A (es) 2009-06-08 2012-01-12 Schering Corp Un antagonista del receptor de trombina y tableta con dosificacion fija de clopidogrel.
TWI393716B (zh) 2009-08-04 2013-04-21 Merck Sharp & Dohme 作為ｉｘａ因子抑制劑之雜環化合物
ES2532902T3 (es) 2010-04-16 2015-04-01 Sanofi Piridil-vinil-pirroles tricíclicos como inhibidores de PAR1
PL2558462T3 (pl) 2010-04-16 2015-03-31 Sanofi Sa Pirydylo-winylo-pirazolo-chinoliny jako inhibitory PAR1
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
EP2822557B1 (en) 2012-03-06 2017-08-23 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
US9604971B2 (en) 2013-07-22 2017-03-28 Aralez Pharmaceuticals Trading Dac Co-crystal of the PAR-1 receptor antagonists vorapaxar and aspirin
EP3035929B1 (en) * 2013-08-22 2024-07-03 Merck Sharp & Dohme LLC 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
US9808473B2 (en) 2013-08-22 2017-11-07 Merck Sharp & Dohme Corp. Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
WO2015026685A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TW201738221A (zh) * 2016-04-22 2017-11-01 Jiangsu Tasly Diyi Pharmaceutical Co Ltd 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
ES3048448T3 (en) 2020-07-22 2025-12-10 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
US12286429B2 (en) 2021-07-22 2025-04-29 Janssen Pharmaceutica Nv 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
TW197435B (es) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
GB9102862D0 (en) * 1991-02-11 1991-03-27 Erba Carlo Spa N-imidazolyl derivatives of substituted or alkoxymino tetrahydronaphthalenes and chromans
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
KR100393492B1 (ko) * 1997-11-25 2003-08-02 쉐링 코포레이션 트롬빈 수용체 길항제
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
ES2291323T3 (es) 2000-06-15 2008-03-01 Schering Corporation Antagonistas de receptores de trombina.
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
MXPA04003610A (es) 2001-10-18 2004-07-27 Schering Corp Analogos de himbacina como antagonistas del receptor de trombina.

Also Published As

Publication number Publication date
TWI343919B (en) 2011-06-21
IL164585A0 (en) 2005-12-18
EP1860106B1 (en) 2010-01-20
AU2003221932B2 (en) 2007-11-22
PE20040412A1 (es) 2004-07-12
EP1860106A1 (en) 2007-11-28
HK1070887A1 (en) 2005-06-30
DE60317493T3 (de) 2018-07-12
KR101026929B1 (ko) 2011-04-04
ATE494284T1 (de) 2011-01-15
BRPI0309309B1 (pt) 2018-09-04
DE60317493D1 (en) 2011-01-13
US7713999B2 (en) 2010-05-11
ES2297150T7 (es) 2012-03-16
FR15C0047I2 (fr) 2016-05-06
DE60317493T2 (de) 2008-09-18
JP4558331B2 (ja) 2010-10-06
LTC1495018I2 (lt) 2017-04-10
US20070270439A1 (en) 2007-11-22
NO330500B1 (no) 2011-05-02
NO20044963L (no) 2004-11-15
CA2482858C (en) 2010-11-30
ATE378330T1 (de) 2007-11-15
EP1495018A1 (en) 2005-01-12
NO2015016I1 (no) 2015-07-20
BRPI0309309B8 (pt) 2021-05-25
PL373332A1 (en) 2005-08-22
SG164279A1 (en) 2010-09-29
ATE455774T1 (de) 2010-02-15
RU2004133375A (ru) 2005-07-10
CY1111363T1 (el) 2015-08-05
TW200404068A (en) 2004-03-16
CN1659162B (zh) 2011-08-31
RU2329264C9 (ru) 2009-04-20
AU2003221932A1 (en) 2003-11-03
PT1495018E (pt) 2008-02-19
JP2010132710A (ja) 2010-06-17
PT2065384E (pt) 2011-03-16
PL214718B1 (pl) 2013-09-30
ES2297150T3 (es) 2008-05-01
CY2015029I1 (el) 2016-04-13
RU2008106401A (ru) 2009-08-27
BR0309309A (pt) 2005-02-15
DK2065384T3 (da) 2011-05-02
ES2338171T3 (es) 2010-05-04
RU2329264C2 (ru) 2008-07-20
NZ535880A (en) 2007-11-30
SI1495018T1 (sl) 2008-04-30
CY2015029I2 (el) 2016-04-13
EP1495018B3 (en) 2011-03-16
NL300746I1 (es) 2016-01-21
US7304078B2 (en) 2007-12-04
EP1495018B1 (en) 2007-11-14
NO2015016I2 (no) 2015-07-09
EP2065384B1 (en) 2011-01-05
US20030216437A1 (en) 2003-11-20
KR20040099441A (ko) 2004-11-26
SI2065384T1 (sl) 2011-05-31
NZ575139A (en) 2010-08-27
EP2065384A1 (en) 2009-06-03
DK1495018T3 (da) 2008-02-18
LU92759I2 (en) 2015-08-31
DE60331114D1 (de) 2010-03-11
MY144040A (en) 2011-07-29
ES2357876T3 (es) 2011-05-03
CA2482858A1 (en) 2003-10-30
EP2062890A1 (en) 2009-05-27
AR039570A1 (es) 2005-02-23
FR15C0047I1 (es) 2015-08-28
NL300746I2 (es) 2016-01-21
JP2005528406A (ja) 2005-09-22
EP1982984B1 (en) 2013-02-13
HK1129893A1 (en) 2009-12-11
WO2003089428A1 (en) 2003-10-30
ZA200408342B (en) 2006-05-31
DE60335679D1 (de) 2011-02-17
EP1982984A3 (en) 2008-10-29
EP1982984A2 (en) 2008-10-22
CN1659162A (zh) 2005-08-24
IL164585A (en) 2010-11-30
CY1107184T1 (el) 2012-10-24
HK1123302A1 (en) 2009-06-12
EP2062890B1 (en) 2011-01-05
MXPA04010308A (es) 2005-02-03
US20070179187A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
ECSP045368A (es) "antagonistas de los receptores de trombina"
CO5570668A2 (es) Derivados triciclicos sustituidos de himbacina que son antagonistas del receptor de trombina y composiciones farmaceuticas que los contienen
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
ES2092316T3 (es) Agentes antianginosos de purinona.
PE20090441A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
AR049696A1 (es) Derivados de indol
AR043998A1 (es) Acidos fenoxiaceticos
MX2009003761A (es) Derivados biciclicos y triciclicos como antagonistas del receptor de trombina.
AR036044A1 (es) Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma
DE60303381D1 (de) Neue indolylpiperidin-derivate als potente antihistaminische und antiallergische mittel
AR044543A1 (es) Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa
ECSP077372A (es) Antagonistas del receptor de trombina
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
AR017189A1 (es) Antagonistas del receptor de trombina triciclico sustituido, composicion farmaceutica que lo contiene y su uso para la manufactura de un medicamento
AR035605A1 (es) Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
AR051334A1 (es) Derivados de 2- amido-4-feniltiazol
AR063095A1 (es) Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina
AR056883A1 (es) Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3
AR061185A1 (es) Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
AR036092A1 (es) Un derivado de benzoxazepina, su uso y una composicion farmaceutica que lo comprende
AR035247A1 (es) Derivados de piperidinacarboxamida, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen
AR042830A1 (es) Acidos carboxilicos y derivados utiles para el tratamiento y la prevencion de diabetes y dislipidemia; composiciones farmaceuticas y medicamentos.